Leave a little sharper than you arrived.

Efgartigimod delivers sustained benefits for all myasthenia gravis subtypes — even those without detectable antibodies

A phase 3 trial shows efgartigimod works across all forms of generalized myasthenia gravis (gMG), including patients who lack detectable antibodies — a group historically excluded from clinical research. Benefits deepened with repeated treatment cycles, with more patients achieving near-symptom-free status over time. The FDA has already expanded efgartigimod's indication to cover all gMG patients, regardless of antibody status.